Clinical Trials Logo
  1. Home
  2. Staphylococcus Aureus Bacteremia
  3. NCT01701219

Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia

Staphylococcus Aureus Bacteremia Clinical Trial

Official title:
A Multicenter, 2-Cohort Study to Describe the Safety and Efficacy of Ceftaroline Fosamil in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia

Clinical Trial Summary

This is a study of safety and efficacy of ceftaroline fosamil in Subjects with Staphylococcus aureus Bacteremia or with Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia persisting after at least 72 hours of vancomycin and/or daptomycin treatment.

Clinical Trial Description

Subjects with either S. aureus bacteremia or persistent MRSA bacteremia will be treated with open label ceftaroline fosamil, safety will be monitored and clearance of bacteremia will be evaluated. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01701219
Study type Interventional
Source Forest Laboratories
Contact
Status Completed
Phase Phase 4
Start date January 2013
Completion date July 2014
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05862025 - Evaluation of the Usefulness of Echocardiography in Patients With Staphylococcus Aureus Bacteremia (ET-AUREUS Study). N/A
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Recruiting NCT00622882 - Early Infectious Disease Consultations in Staphylococcus Aureus Bacteremia N/A
Recruiting NCT06168474 - Evaluating Simplified Layered Consent for Clinical Trials N/A
Completed NCT03163446 - Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia Phase 2
Not yet recruiting NCT06336824 - Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia Phase 3
Completed NCT02357966 - A Study of the Safety and Efficacy of 514G3 in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus Phase 1/Phase 2
Recruiting NCT04886284 - Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia Phase 2
Terminated NCT03089697 - Phase IIa Clinical Study of N-Rephasin® SAL200 Phase 2
Recruiting NCT03514446 - Seven Versus Fourteen Days of Treatment in Uncomplicated Staphylococcus Aureus Bacteremia Phase 4
Withdrawn NCT03761953 - Oritavancin for Staphylococcus Aureus Infections in Opioid Users Phase 4
Recruiting NCT06249451 - Staphylococcus Aureus Bacteraemia (SAB)-Support-Study N/A
Recruiting NCT02098850 - Staphylococcus Aureus Bacteraemia in Adults N/A
Recruiting NCT05137119 - Staphylococcus Aureus Network Adaptive Platform Trial Phase 4
Completed NCT03908086 - Bloodstream Infections in Patients With Rheumatoid Arthritis
Terminated NCT04160468 - Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase Phase 3
Completed NCT03138733 - Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia Phase 3
Completed NCT02476487 - The Benefit of FDG PET CT in the Treatment Algorithm of Staphylococcus Aureus Bacteremia N/A
Recruiting NCT05184764 - Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia Phase 1/Phase 2
Completed NCT01971762 - Staphylococcus Aureus Bacteremia: Impact of an Intervention Program in Improving the Clinical Management and Review of the Clinical and Molecular Epidemiology N/A